# Dianthus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dianthus-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.dianthustx.com
- Total disclosed funding: $100M
- Latest round: Series A (Apr 6, 2022)
- Investors on record: 7

## About

Founded in 2019 and based in Massachusetts, US, Dianthus Therapeutics, Inc. is a biotechnology firm that focuses on the development of antibody therapeutics and pharmaceuticals. In April 2022, Dianthus Therapeutics, Inc. raised USD 100 million in Series A funding from 5AM Ventures including Avidity Partners Management, Fidelity Investments, Wedbush Securities, Fairmount Funds Management, Tellus BioVentures, and Venrock. As of 2022, Marino Garcia is the CEO of the company. 

The company designs and delivers monoclonal antibodies with selectivity and potency over existing complement therapies. The firm is developing DNTH103, a monoclonal antibody that targets the active form of complement C1s, allowing for a lower dosage volume and less frequent subcutaneous administration, which is further strengthened by half-life extension technology. Dianthus also develops DNTH200 and DNTH300. 

The organization plans to use the April 2022 funding to expand its team, advance its DNTH103 program to the clinic in 2022, and accelerate additional discovery pipeline programs.

## Funding rounds

- Series A, Apr 6, 2022, $100M — Venrock, 5AM Ventures, Fidelity Investments, Fairmount Funds Management, Wedbush Securities, Avidity Partners Management, Tellus BioVentures

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series A
- Fairmount Funds Management — Series A
- Wedbush Securities — Series A
- Avidity Partners Management — Series A
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Series A